Inhibrx Biosciences, Inc.
MANHARD KIMBERLY sold 1,500 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at an average of $109.03 ($105.05–$111.78, $0.16M total) across 3 trades over 2026-09-11 to 2026-09-15.
MANHARD KIMBERLY sold 1,000 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at an average of $115.47 ($115.14–$115.80, $0.12M total) across 2 trades over 2026-09-08 to 2026-09-09.
On September 9, 2026, significant insider trading activity was reported. Alumis Inc. (ALMS) director acquired $10.7M in shares, while NVIDIA (NVDA) director sold $235.6M. Greenwave (GWAV) CEO bought $8M in shares, and BELITE BIO (BLTE) executives sold $31.9M. Workday (WDAY) director sold $17.9M in shares. Dell (DELL) insiders sold $48.1M. Inhibrx (INBX) and Cytosorbents (CTSO) directors also made notable purchases.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning INBX (Inhibrx Biosciences, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent INBX coverage spans insider activity, earnings and financial news.
In the last 30 days, INBX insiders filed 13 SEC Form 4 transactions — 8 purchases ($3.5M) and 5 sales ($279K). The most active reporter was Lappe Mark, Chief Executive Officer, with 6 filings.
A modest insider sale by a director may signal limited confidence but the amount is small relative to market cap.
Small insider sale by a director; likely limited price impact.
Minor insider purchase may be neutral to positive.
A modest insider purchase by a director, indicating confidence but limited market impact.
Insider purchase indicates confidence from a board member.
AlphAI scores every news story that mentions INBX with an AI model for sentiment and relevance, and aggregates insider trades from Inhibrx Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
MANHARD KIMBERLY sold 1,500 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at an average of $109.03 ($105.05–$111.78, $0.16M total) across 3 trades over 2026-09-11 to 2026-09-15.
1 min readMANHARD KIMBERLY sold 1,000 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at an average of $115.47 ($115.14–$115.80, $0.12M total) across 2 trades over 2026-09-08 to 2026-09-09.
1 min readOn September 9, 2026, significant insider trading activity was reported. Alumis Inc. (ALMS) director acquired $10.7M in shares, while NVIDIA (NVDA) director sold $235.6M. Greenwave (GWAV) CEO bought $8M in shares, and BELITE BIO (BLTE) executives sold $31.9M. Workday (WDAY) director sold $17.9M in shares. Dell (DELL) insiders sold $48.1M. Inhibrx (INBX) and Cytosorbents (CTSO) directors also made notable purchases.
3 min readKayyem Jon Faiz purchased 5,000 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at $113.52 ($0.57M total) on 2026-09-08.
1 min readFORSYTH DOUGLAS purchased 2,500 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at $114.65 ($0.29M total) on 2026-09-08.
1 min readLappe Mark (Chief Executive Officer) purchased 25,000 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at an average of $105.82 ($99.29–$112.28, $2.65M total) across 6 trades on 2026-09-08.
1 min readInhibrx Biosciences (NASDAQ:INBX) shares rose 6% after reporting positive Phase 2 trial results for INBRX-106 combined with pembrolizumab in head and neck cancer. The combination showed a 48.3% response rate vs. 26.5% for pembrolizumab alone. The study included 63 patients, with notable improvements in HPV-positive patients. The company plans to expand the trial and align with the FDA for a potential accelerated pathway.
2 min readInhibrx Biosciences (Nasdaq: INBX) reported Q2 2026 results. It received $100.0 million from Oxford Finance under a loan amendment that allows up to $325.0 million gross proceeds. Cash rose to $219.5 million as of Aug. 6. Q2 R&D was $23.9 million, net loss $36.7 million ($2.34/share). FDA accepted its ozekibart BLA with PDUFA April 14, 2027.
4 min readInhibrx Biosciences, Inc. (INBX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inhibrx Reports Second Quarter 2026 Financial Results San Diego, CA, August 13, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the second quarter of 2026. The biopharmaceutical company has two program
6 min readInhibrx Biosciences (Nasdaq: INBX) reported Q2 2026 results and said the FDA accepted its BLA for ozekibart (INBRX-109) in conventional chondrosarcoma, assigning a PDUFA goal date of April 14, 2027. The company also amended its Oxford Finance loan for up to $325.0 million. Q2 net loss was $36.7 million; cash was $219.5 million as of Aug. 6, 2026.
4 min read
